ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $235,000 | -19.8% | 5,340 | -10.0% | 0.00% | 0.0% |
| Q1 2021 | $293,000 | -34.9% | 5,932 | -44.5% | 0.00% | -50.0% |
| Q4 2020 | $450,000 | -6.4% | 10,680 | +1.6% | 0.00% | -20.0% |
| Q3 2020 | $481,000 | -8.6% | 10,510 | +0.3% | 0.01% | -16.7% |
| Q2 2020 | $526,000 | -1.1% | 10,478 | +1.3% | 0.01% | -14.3% |
| Q1 2020 | $532,000 | +18.2% | 10,342 | +42.1% | 0.01% | +75.0% |
| Q4 2019 | $450,000 | +103.6% | 7,280 | +97.7% | 0.00% | +100.0% |
| Q3 2019 | $221,000 | +820.8% | 3,683 | +1215.4% | 0.00% | – |
| Q2 2019 | $24,000 | -7.7% | 280 | +1.8% | 0.00% | – |
| Q1 2019 | $26,000 | +30.0% | 275 | -4.5% | 0.00% | – |
| Q4 2018 | $20,000 | -9.1% | 288 | +9.5% | 0.00% | – |
| Q3 2018 | $22,000 | +57.1% | 263 | +115.6% | 0.00% | – |
| Q2 2018 | $14,000 | +75.0% | 122 | +16.2% | 0.00% | – |
| Q1 2018 | $8,000 | -27.3% | 105 | -44.1% | 0.00% | – |
| Q4 2017 | $11,000 | – | 188 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |